indication

For the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure.

pharmacology

Deslanoside is a cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.

mechanism of action

Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Deslanoside also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

toxicity

Symptoms of overdose include ventricular tachycardia, ventricular fibrillation, progressive bradyarrhythmias, or heart block.

absorption

Little absorption from the gastrointestinal tract (40%).

half life

36 hours

drug interactions

Bendroflumethiazide: Possible electrolyte variations and arrhythmias

Bumetanide: Possible electrolyte variations and arrhythmias

Chlorthalidone: Possible electrolyte variations and arrhythmias

Ethacrynic acid: Possible electrolyte variations and arrhythmias

Furosemide: Possible electrolyte variations and arrhythmias

Hydrochlorothiazide: Possible electrolyte variations and arrhythmias

Indapamide: Possible electrolyte variations and arrhythmias

Metolazone: Possible electrolyte variations and arrhythmias